Research programme: 3-phosphoinositide-dependent protein kinase 1 inhibitors - Novartis
Alternative Names: PDK1 inhibitors - NovartisLatest Information Update: 16 Jul 2016
At a glance
- Originator Novartis
- Class Quinazolines
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 26 Aug 2010 Preclinical trials in Cancer in USA (unspecified route)